Kiromic BioPharma (KRBP) Form 3 Kiromic Biopharma / Daniel Grant Clark ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Clark Daniel Grant

(Last) (First) (Middle)

C/O KIROMIC BIOPHARMA, INC.

7707 FANNIN, SUITE 140

(Street)

HOUSTON TX 77054

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/30/2021

3. Issuer Name and Ticker or Trading Symbol
Kiromic Biopharma, Inc. [ KRBP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Interim CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6,866	D
Restricted Stock Units	29,516(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	06/08/2030	Common Stock	5,152	17.47	D

Explanation of Responses:

1. The reported restricted stock units will be settled in an equal number of shares of common stock, and vest according to the same schedule: 20% of the restricted stock units vested on June 30, 2021, and 20% of the restricted stock units will vest on each of (i) June 30, 2022, (ii) June 30, 2023, (iii) June 30, 2024, and (iv) June 30, 2025.

2. The original number of shares subject to the stock option was 18,000, and the initial exercise price was $5.00. The Company underwent a 1-for-3.494 reverse stock split which adjusted the amount of shares subject to the option and the exercise price accordingly. Subject to continuing employment, the stock option vested with respect to 572 shares on June 8, 2020, with the remaining shares vesting at a rate of 1/32 per month for the next 32 months. As of the filing this report, 2,862 shares have vested and 2,290 shares remain unvested.

	/s/ Daniel Grant Clark	10/14/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.